P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL

• Jason Gotlib,
• Mariana Castells,
• Hanneke Oude Elberink,
• Frank Siebenhaar,
• Karin Hartmann,
• Sigurd Broesby-Olsen,
• Tracy I. George,
• Jens Panse,
• Ivan Alvarez-Twose,
• Deepti Radia,
• Tsewang Tashi,
• Cristina Bulai Livideanu,
• Vito Sabato,
• Paul Van Daele,
• Sonia Cerquozzi,
• Ingunn Dybedal,
• Andreas Reiter,
• Celalettin Ustun,
• Philippe Schafhausen,
• Prithviraj Bose,
• Daniel J. Deangelo,
• Lindsay Rein,
• Pankit Vachhani,
• Massimo Triggiani,
• Mark Rafferty,
• Nauman Butt,
• Stephen Oh,
• Friederike Wortmann,
• Johanna Ungerstedt,
• Minakshi Taparia,
• Andrew T. Kuykendall,
• Cecilia Arana Yi,
• Mattias Mattsson,
• William Shomali,
• Matthew Giannetti,
• Ilda Bidollari,
• Hui-Min Lin,
• Robyn Scherber,
• Maria Roche,
• Cem Akin,
• Marcus Maurer

Affiliations

Jason Gotlib

1 Stanford Cancer Institute/Stanford University School of Medicine, Stanford, United States

Mariana Castells

2 Brigham and Women’s Hospital, Department of Medicine, Division of Allergy and Clinical Immunology, Boston, United States

Hanneke Oude Elberink

3 University Medical Center, University of Groningen, Department of Allergology, Groningen, The Netherlands

Frank Siebenhaar

4 Institute of Allergology, Charité –Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany

Karin Hartmann

5 University Hospital Basel and University of Basel, Division of Allergy, Department of Dermatology, and Department of Biomedicine, Basel, Switzerland

Sigurd Broesby-Olsen

6 Odense University Hospital, Department of Dermatology and Allergy Centre, Odense, Denmark

Tracy I. George

7 University of Utah School of Medicine, ARUP Laboratories, Department of Pathology, Salt Lake City, United States

Jens Panse

8 University Hospital Aachen, Medical Faculty, RWTH Aachen University, Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, Aachen, Germany

Ivan Alvarez-Twose

9 Institute of Mastocytosis Studies of Castilla-La Mancha (CLMast), Virgen del Valle Hospital, Toledo, Spain

Deepti Radia

10 Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom

Tsewang Tashi

11 Huntsman Cancer Institute, University of Utah, Salt Lake City, United States

Cristina Bulai Livideanu

12 Toulouse University Hospital - Larrey Hospital, Department de dermatologie Expert Centre of Mastocytosis (CEREMAST) CHU de Toulouse, Toulouse, France

Vito Sabato

13 University of Antwerp and Antwerp University Hospital, Department of Immunology Allergology and Rheumatology, Antwerp, Belgium

Paul Van Daele

14 Erasmus Medical Center, Rotterdam, The Netherlands

Sonia Cerquozzi

15 University of Calgary, Foothills Medical Centre603 South Tower, Calgary, Canada

Ingunn Dybedal

16 Oslo University Hospital - Rikshospitalet, Department of Hematology, Oslo, Norway

Andreas Reiter

17 University Hospital Mannheim, Heidelberg University, Department of Hematology and Oncology, Mannheim, Germany

Celalettin Ustun

18 Rush Medical College, Chicago, United States

Philippe Schafhausen

19 University Medical Center Hamburg - Eppendorf, Hamburg, Germany

Prithviraj Bose

20 The University of Texas MD Anderson Cancer Center, Houston, United States

Daniel J. Deangelo

21 Dana-Farber Cancer Institute, Boston, United States

Lindsay Rein

22 Duke University, School of Medicine, Durham, United States

Pankit Vachhani

23 University of Alabama at Birmingham, Birmingham, United States

Massimo Triggiani

24 University of Salerno, Division of Allergy and Clinical Immunology, Salerno, Italy

Mark Rafferty

25 The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Nauman Butt

26 The Clatterbridge Cancer Centre, Wirral, United Kingdom

Stephen Oh

27 Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, Saint Louis, United States

Friederike Wortmann

28 Universitätsklinikum Schleswig-Holstein Lübeck, Klinik für Hämatologie/Onkologie, Campus Lübeck, Lübeck, Germany

Johanna Ungerstedt

29 Karolinska University Hospital ME Hematology R51, Stockholm, Sweden

Minakshi Taparia

30 University of Alberta, Edmonton, Canada

Andrew T. Kuykendall

31 H Lee Moffitt Cancer Center, Tampa, United States

Cecilia Arana Yi

32 Mayo Clinic, Phoenix, United States

Mattias Mattsson

33 Akademiska sjukhuset, Hematologmottagningen 101 A, Uppsala, Sweden

William Shomali

1 Stanford Cancer Institute/Stanford University School of Medicine, Stanford, United States

Matthew Giannetti

34 Brigham and Women’s Hospital, Department of Medicine, Boston, United States

Ilda Bidollari

35 Blueprint Medicines Corporation, Cambridge, United States

Hui-Min Lin

35 Blueprint Medicines Corporation, Cambridge, United States

Robyn Scherber

35 Blueprint Medicines Corporation, Cambridge, United States

Maria Roche

35 Blueprint Medicines Corporation, Cambridge, United States

Cem Akin

36 University of Michigan, Ann Arbor, United States

Marcus Maurer

4 Institute of Allergology, Charité –Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany